Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool

• [02/26/2015 04:45 PST] CHRS Expected to Trade Up Short Term
• [02/18/2015 05:05 PST] CHRS Expected to Trade Down After Bearish Patterns Develop
• [02/12/2015 05:29 PST] CHRS Expected to Trade Down After Bearish Patterns Develop
• [02/06/2015 05:07 PST] CHARMING SHOPPES (NASDAQ:CHRS), Up By 20.54% ($5.01) From $24.390 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [02/06/2015 05:07 PST] CHRS Expected to Trade Up After Bullish Patterns Develop
• [01/20/2015 04:44 PST] CHRS Expected to Trade Down After Bearish Patterns Develop